What Does Wall Street Think About Vaxcyte (PCVX)?

Core Insights - Vaxcyte, Inc. (NASDAQ:PCVX) is recognized as a strong buy stock by Wall Street, with varying price targets from different analysts [1][2][3] - The analyst consensus on Vaxcyte is a Strong Buy, with a median price target of $33.98, indicating a potential upside of 241.38% from current levels [3] Analyst Ratings - Goldman Sachs initiated coverage with a Neutral rating and a price target of $38 on September 12 [1] - Mizuho Securities maintained a Buy rating with a price target of $163.00 on August 16 [2] - Guggenheim reiterated a Buy rating with a price target of $116 on August 7 [2] Company Overview - Vaxcyte, Inc. is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines [3] - The company specializes in broad-spectrum conjugate and novel protein vaccines aimed at preventing or treating bacterial infectious diseases [3] - Vaxcyte employs advanced chemistry and modern synthetic techniques to re-engineer the creation of complex vaccines [3]